IBEX 35
10.992,30 -73,80 (-0,67%) Euro Stoxx 50
4.839,14 -96,36 (-1,95%) Dólar/Euro
1,0709 -0,0033 (-0,31%) Petróleo Brent
82,60 -0,15 (-0,18%) Oro
2.348,40 +30,40 (+1,31%) Bitcoin EUR
62.134,82 +300,61 (+0,49%)
Kadimastem Ltd (KDST.TA)
Kadimastem Ltd
Pinchas Sapir 7
Ness Ziona 74140
Israel
972 73 797 1600
https://www.kadimastem.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 12
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Asaf Shiloni | Chief Executive Officer | 1,14M | N/A | 1970 |
| Mr. Uri Ben-Or | Chief Financial Officer | 222k | N/A | 1970 |
| Dr. Arik Hasson Ph.D. | Executive Vice President of Business Development | 585k | N/A | 1962 |
| Dr. Michal Harel Izrael | Vice President of Research & Development for ALS and Neurodegenerative Diseases | 626k | N/A | 1977 |
| Prof. Michel Revel M.D., Ph.D. | Co-Founder, Chief Scientist, Head of the Scientific Advisory Board & Director | 480k | N/A | 1938 |
| Mr. Yossi Ben-Yossef | Honorary President & Strategic Consultant | 1,14M | N/A | 1957 |
| Mr. Olivier Samuel | VP of European Business Development & Director | 146k | N/A | 1974 |
Descripción
Kadimastem Ltd, a biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases. Its products in pipeline include AstroRx, a clinical grade human astrocytes that is in Phase 1/2a clinical trial for the treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases; and IsletRx, a clinical grade pancreatic islet cell therapy treatment for diabetes. The company was incorporated in 2008 and is based in Ness Ziona, Israel.
Gobierno corporativo
El ISS Governance QualityScore de Kadimastem Ltd, a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
